198 related articles for article (PubMed ID: 35583460)
1. Advances in Nanomaterial-Based Platforms to Combat COVID-19: Diagnostics, Preventions, Therapeutics, and Vaccine Developments.
Mahmud N; Anik MI; Hossain MK; Khan MI; Uddin S; Ashrafuzzaman M; Rahaman MM
ACS Appl Bio Mater; 2022 Jun; 5(6):2431-2460. PubMed ID: 35583460
[TBL] [Abstract][Full Text] [Related]
2. Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms.
Jafari A; Danesh Pouya F; Niknam Z; Abdollahpour-Alitappeh M; Rezaei-Tavirani M; Rasmi Y
Mol Biol Rep; 2022 Jun; 49(6):4943-4957. PubMed ID: 35235159
[TBL] [Abstract][Full Text] [Related]
3. Primed for global coronavirus pandemic: Emerging research and clinical outcome.
Ahamad S; Branch S; Harrelson S; Hussain MK; Saquib M; Khan S
Eur J Med Chem; 2021 Jan; 209():112862. PubMed ID: 33070079
[TBL] [Abstract][Full Text] [Related]
4. Emerging nanotechnology role in the development of innovative solutions against COVID-19 pandemic.
Bhutta ZA; Kanwal A; Ali M; Kulyar MF; Yao W; Shoaib M; Ashar A; Mahfooz A; Ijaz M; Ijaz N; Asif M; Nawaz S; Mahfooz MR; Kanwal T
Nanotechnology; 2021 Sep; 32(48):. PubMed ID: 34320471
[TBL] [Abstract][Full Text] [Related]
5. Nanomedicine for the SARS-CoV-2: State-of-the-Art and Future Prospects.
Varahachalam SP; Lahooti B; Chamaneh M; Bagchi S; Chhibber T; Morris K; Bolanos JF; Kim NY; Kaushik A
Int J Nanomedicine; 2021; 16():539-560. PubMed ID: 33519200
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the vaccine development for the prophylaxis of SARS Covid-19.
Kumar V; Kumar S; Sharma PC
Int Immunopharmacol; 2022 Oct; 111():109175. PubMed ID: 35994853
[TBL] [Abstract][Full Text] [Related]
7. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
8. A perspective on SARS-CoV-2 virus-like particles vaccines.
Gao X; Xia Y; Liu X; Xu Y; Lu P; Dong Z; Liu J; Liang G
Int Immunopharmacol; 2023 Feb; 115():109650. PubMed ID: 36649673
[TBL] [Abstract][Full Text] [Related]
9. Nanotechnologies for the Diagnosis and Treatment of SARS-CoV-2 and Its Variants.
Park E; Choi SY; Kim J; Hildebrandt N; Lee JS; Nam JM
Small Methods; 2023 Jul; 7(7):e2300034. PubMed ID: 37189215
[TBL] [Abstract][Full Text] [Related]
10. Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants.
Chatterjee B; Thakur SS
Expert Rev Vaccines; 2022 Jan; 21(1):47-67. PubMed ID: 34697980
[TBL] [Abstract][Full Text] [Related]
11. Advances in gene-based vaccine platforms to address the COVID-19 pandemic.
Pushparajah D; Jimenez S; Wong S; Alattas H; Nafissi N; Slavcev RA
Adv Drug Deliv Rev; 2021 Mar; 170():113-141. PubMed ID: 33422546
[TBL] [Abstract][Full Text] [Related]
12. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
[TBL] [Abstract][Full Text] [Related]
13. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
14. Nano-engineered tools in the diagnosis, therapeutics, prevention, and mitigation of SARS-CoV-2.
Kamat S; Kumari M; Jayabaskaran C
J Control Release; 2021 Oct; 338():813-836. PubMed ID: 34478750
[TBL] [Abstract][Full Text] [Related]
15. Biotechnological Perspectives to Combat the COVID-19 Pandemic: Precise Diagnostics and Inevitable Vaccine Paradigms.
Aileni M; Rohela GK; Jogam P; Soujanya S; Zhang B
Cells; 2022 Mar; 11(7):. PubMed ID: 35406746
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic.
Shao Y; Wu Y; Feng Y; Xu W; Xiong F; Zhang X
Front Med; 2022 Apr; 16(2):185-195. PubMed ID: 35226300
[TBL] [Abstract][Full Text] [Related]
18. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines.
Fernandes Q; Inchakalody VP; Merhi M; Mestiri S; Taib N; Moustafa Abo El-Ella D; Bedhiafi T; Raza A; Al-Zaidan L; Mohsen MO; Yousuf Al-Nesf MA; Hssain AA; Yassine HM; Bachmann MF; Uddin S; Dermime S
Ann Med; 2022 Dec; 54(1):524-540. PubMed ID: 35132910
[TBL] [Abstract][Full Text] [Related]
19. Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants.
Noor R
Viruses; 2022 Nov; 14(11):. PubMed ID: 36423150
[TBL] [Abstract][Full Text] [Related]
20. Next-Generation Vaccines: Nanovaccines in the Fight against SARS-CoV-2 Virus and beyond SARS-CoV-2.
Mufamadi MS; Ngoepe MP; Nobela O; Maluleke N; Phorah B; Methula B; Maseko T; Masebe DI; Mufhandu HT; Katata-Seru LM
Biomed Res Int; 2023; 2023():4588659. PubMed ID: 37181817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
